Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment

Jianxiong Chan; Gita V Soraya; Lauren Craig; Shah M Uddin; Marian Todaro; Duc H Huynh; Chathurika D Abeyrathne; Lyudmila Kostenko; James McCluskey; Efstratios Skafidas; Patrick Kwan

doi:10.3390/s19163543

Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment

Sensors (Basel). 2019 Aug 14;19(16):3543. doi: 10.3390/s19163543.

Authors

Jianxiong Chan¹, Gita V Soraya^{1

2}, Lauren Craig¹, Shah M Uddin¹, Marian Todaro^{1

3}, Duc H Huynh⁴, Chathurika D Abeyrathne⁴, Lyudmila Kostenko⁵, James McCluskey⁵, Efstratios Skafidas⁴, Patrick Kwan^{6

7}

Affiliations

¹ Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Victoria 3050, Australia.
² Department of Biochemistry, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.
³ Department of Neurology, Royal Melbourne Hospital, Victoria 3050, Australia.
⁴ Department of Electrical and Electronic Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010, Australia.
⁵ Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Victoria 3010, Australia.
⁶ Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Victoria 3050, Australia. patrick.kwan@unimelb.edu.au.
⁷ Department of Neurology, Royal Melbourne Hospital, Victoria 3050, Australia. patrick.kwan@unimelb.edu.au.

Abstract

Pre-treatment screening of individuals for human leukocyte antigens (HLA) HLA-B*57:01 is recommended for the prevention of life-threatening hypersensitivity reactions to abacavir, a drug widely prescribed for HIV treatment. However, the implementation of screening in clinical practice is hindered by the slow turnaround time and high cost of conventional HLA genotyping methods. We have developed a biosensor platform using interdigitated electrode (IDE) functionalized with a monoclonal antibody to detect cells expressing HLA-B*57:01. This platform was evaluated using cell lines and peripheral blood mononuclear cells expressing different HLA-B alleles. The functionalized IDE sensor was able to specifically capture HLA-B*57:01 cells, resulting in a significant change in the impedance magnitude in 20 min. This IDE platform has the potential to be further developed to enable point-of-care HLA-B*57:01 screening.

Keywords: human leukocyte antigen; impedance sensor; interdigitated electrodes; pharmacogenetics; point-of-care diagnostics; protein sensor.

MeSH terms

Alleles
Antibodies, Immobilized / chemistry
Antibodies, Immobilized / immunology
Antibodies, Monoclonal / chemistry
Antibodies, Monoclonal / immunology
Biosensing Techniques / methods*
Dideoxynucleosides / adverse effects*
Dideoxynucleosides / therapeutic use
Drug Hypersensitivity / etiology
Drug Hypersensitivity / prevention & control*
Electrochemical Techniques
Electrodes
HIV Infections / drug therapy
HLA-B Antigens / analysis*
HLA-B Antigens / genetics
HLA-B Antigens / immunology
Humans
Leukocytes, Mononuclear / metabolism*

Substances

Antibodies, Immobilized
Antibodies, Monoclonal
Dideoxynucleosides
HLA-B Antigens
HLA-B*57:01 antigen
abacavir